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anesthetic  (GA).12,13 With the increasing use of multiparametric 
magnetic resonance imaging  (MRI), integrated MRI-TRUS fusion 
biopsies are able to improve detection of significant prostate cancer 
whether by the transrectal14 or TP route.15
Rosario et al.4 recently presented the ProBE study: a multicenter, 
prospective questionnaire study on short-term patient-reported 
outcomes after TRUS biopsy on 1147 men. Using a bespoke 
questionnaire, data relating to pain, infection, and bleeding was 
collected at 7 days and 35 days postprocedure, as well as attitude to 
rebiopsy and healthcare use. They found that despite pain reported in 
43.6%, hematuria in 65.8%, hemoejaculate in 92.6% of men, prostate 
biopsy was tolerated well by most men, with a few troublesome side 
effects in a minority.4 Approximately 20% of men would consider 
further biopsy a moderate or major problem, and that this negative 
attitude to rebiopsy was associated with an unfavorable experience at 
first biopsy.4
The aim of this study was to use the validated patient-reported 
outcome questionnaire from the ProBE study to document the 
INTRODUCTION
Prostate cancer is a significant health problem and a leading cause of 
death in men throughout the developed world.1 Diagnostic approaches 
have evolved from finger guided prostatic biopsies to 12 core 
transrectal-ultrasound-guided (TRUS) biopsies. Despite this, TRUS 
biopsy misses up to one-third of cancers and frequently characterizes 
tumors incorrectly in terms of grade, size, and position.2,3 TRUS can be 
associated with significant pain and distress and Rosario et al.4 reported 
fever in 17.5% of men after TRUS biopsy. Other studies have found a 
hospital admission rate of 5%–6.9% due to infectious complications 
after TRUS biopsy.5–7 In the era of increasing anti-microbial resistance 
of intestinal microorganisms, the transrectal biopsy approach may be 
hampered by rising rates of prostatitis and sepsis.8
Given some of the limitations of TRUS biopsy, there has been 
renewed interest in the role of transperineal (TP) prostate biopsy in 
prostate cancer diagnostics.9 TP biopsies might have a higher rate 
of cancer detection,10 particularly at the apex and anteriorly, with 
significantly lower rates of sepsis,11 but usually require a general 
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occurrence and effect of adverse events, early attitudes to repeat biopsy 
and healthcare resource use in the TP biopsy setting. We hypothesized 
that patient-reported outcomes would be similar between TP biopsy 
and the previously reported TRUS biopsy from Rosario et al.4 Here, we 
present the first prospective evaluation of short-term patient-reported 
outcomes after TP biopsy across centers in the UK and Germany, using 
a validated questionnaire.
MATERIALS AND METHODS
A standardized prospective questionnaire-based cohort study was 
conducted across three centers (Addenbrookes Hospital, Cambridge 
UK; University Hospital Heidelberg, Heidelberg Germany; and Kings 
College Hospital, London), using an adapted version of the previously 
validated ProBE questionnaire.4 The study was registered as a service 
evaluation audit in all centers with the Local Ethics Committees. 
Specifically these were Cambridge University Hospitals Ethics 
Committee, Addenbrookes Hospital, UK; The University Hospital 
Heidelberg Ethics Review Board and Kings College Hospital, London 
Ethics Committee.
Population
All men undergoing TP biopsy  (diagnostic primary, second, or 
active surveillance rebiopsy) between February and November 2013 
were asked to self-complete the questionnaire immediately after 
biopsy (baseline) and at follow-up between 7 and 14 days after the 
biopsy. Three hundred eighty-six men were included in the study 
divided between primary and secondary TP biopsy.
Patients were given written information on the study as well as 
instructions on completing the questionnaire. Baseline data including 
age, Hospital Anxiety and Depression Scale (HADS score), urinary, bowel 
and sexual symptoms were assessed using the validated International 
Continence Society - male, International Consultation on Incontinence 
Modular Questionnaire-urinary incontinence and University of 
California, Los Angeles Prostate Cancer index questionnaires, 
International Prostate Symptom Score (IPSS), and International Index 
of Erectile Function 5 (IIEF-5) shortened questionnaire.
Biopsy
TP biopsies were carried out as a day case surgical procedure.9,16 
Under general anesthetic and in the lithotomy position, with antibiotic 
prophylaxis, standardized “Ginsburg protocol”8 cores were sampled by 
the transperineal route. Briefly, this involves taking 4 cores from each of 
the anterior, mid, and posterior prostate sectors targeting the peripheral 
zone, avoiding the urethra. In addition, further cores are targeted to 
cancer-suspicious MRI visible lesions if present. Multiparametric 
MRIs were read by experienced specialist uroradiologists and any 
“target” lesions identified, with prostate and lesion reporting occurring 
according to the European Society of Uro-Radiology standards shortly 
before biopsy.17 One center used the MRI cognitively/visually and two 
centers with the support of MRI-ultrasound fusion software (BiopSee™, 
Darmstadt, Germany). In total, 24–40 cores were taken. After recovery, 
men were observed until they had voided after which they were 
discharged on the same day. All men were provided with written 
information regarding postbiopsy instructions.
Outcome measures
The ProBE questionnaire is well described in the original publication.4 
A bespoke questionnaire was created and validated to measure the 
frequency and effect of symptoms related to pain, infection, and 
bleeding; patient attitude to repeat biopsy and participant healthcare 
resource use was also evaluated.
For use in patients undergoing TP biopsies, the appropriate 
questions were altered to allow for the use of GA. The questionnaire 
had been validated in English-speaking patients only by the ProBE 
team. For the use in German patients, we followed a formal translation 
and retranslation process to ensure accurate interpretation. The 
questionnaire was translated by a German with good knowledge of the 
English language from English into German and retranslated back into 
English by another German urologist resident in the UK.
Symptoms
Using a Likert-type scale, men were asked to described pain and 
discomfort immediately after the procedure and at follow-up describing 
it as “none,” “mild,” “moderate,” or “severe.” Complications such as 
hematuria, hematochezia, hemoejaculate, fever, shivers, and pain 
were self-reported as absent or present and then graded from “none,” 
“minor,” “moderate,” or “major” to assess the scale of the problem. 
Alongside, urinary, bowel, and sexual symptoms were assessed using 
the validated International Continence Society - male, International 
Consultation on Incontinence Modular Questionnaire-urinary 
incontinence and University of California, Los Angeles Prostate Cancer 
index questionnaires,18–20 International Prostate Symptom Score,21 and 
International Index of Erectile Function22 at baseline and follow-up.
Attitude to rebiopsy
To assess attitudes to future biopsies, men were asked “how much of 
a problem would you find having another biopsy in the future?” and 
asked to rate it on a four-point Likert-type scale (not a problem, minor 
problem, moderate problem, major problem) and “how you would 
describe the procedure to a friend?” (Minor, moderate, or major).
Use of healthcare services
Men were asked in the questionnaire about contact with healthcare, 
whether they had been prescribed any analgesics or antibiotics or were 
catheterized. For all the questions enquiry was made as to the severity 
of the problem (none, minor, moderate, or major).
Classifying adverse events
At follow-up review, adverse events were recorded and classified by 
the clinician by the Clavien-Dindo classification.23
Data analysis
SPSS  (IBM Corporation Released 2012 IBM SPSS Statistics for 
Windows, Version 21.0. Armonk, NY, USA) was used for data analysis. 
The proportion of men experiencing each outcome was presented 
with 95% confidence intervals (CIs) calculated using Wilson’s method. 
A P value of 0.05 or less was considered statistically significant. The 
effect of risk factors on binary outcome measures was estimated as odds 
ratios (ORs) using logistic regression adjusted for center. OR with CIs 
and P values were calculated.
RESULTS
Of 389 men who were included in the study, 201 men answered 
both questionnaires (response rate = 51.6%). Baseline demographic 
measures are shown in Table 1. The nonresponders were chased up by 
telephone calls and contact to referring physicians to ensure that they 
were not lost to follow-up, or admitted with a serious complication. 
The main reasons for noncompletion of the study were either forgetting 
to fill in questionnaires, not filling in follow-up questionnaires, or 
returning documents unfilled.
Symptoms and significance
Immediately after biopsy 43/201 (21.4%) felt men felt light-headed, 
syncopal, or suffered syncope. Fifty-three percent of men felt 
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discomfort after biopsy (with 95% scoring <5 in a 0–10 scale). Twelve 
out of 196 (6.1%) men felt pain immediately after the procedure.
Table 2 highlights the number of men at follow-up questioning 
who had suffered pain, fever, shivers, hematuria, hematochezia, 
hemoejaculate, nausea or felt unwell. Table  2 shows in whom this 
reported symptom was a moderate or serious problem, in those that 
answered this part of the question (not all men gave the severity of 
the problem). Over one-third of men reported no sexual activity after 
biopsy (n = 70/187). Despite the high incidence of symptoms, it was 
not a moderate or serious problem for most, apart from hemoejaculate 
which 31 men suffered. There were no inpatient admissions due to 
complications (hematuria, sepsis, or catheterization).
Sexual and urinary matters
Table  3 shows the IPSS, quality of life  (QoL), and IIEF scores 
immediately after and at follow-up. In general, most men fell into the 
“moderate” symptom group with regards to IPSS at both timepoints 
with no urinary symptom deterioration. This was accompanied by a 
QoL score, which was “mostly pleased” at both intervals. There was 
a significant and marked reduction in erectile function on repeat 
questioning at a later timepoint (IIEF score 16.1 vs. 13.2; P < 0.001; 
Table 3).
Attitude to rebiopsy
Just after the procedure, 14 out of 196 men (7.1%) said a repeat biopsy 
would be a significant problem. On repeat questioning, 25 out of 199 
men (12.6%) said repeat biopsy would be a significant problem.
When comparing attitude to biopsy at follow-up with age, prostate 
volume, pain or aspirin use, using a multiple logistic regression model, 
there was no effect overall (OR = 1.2; 95% CI: 0.456–3.3) (Table 4).
Contact with healthcare
In all, 11 out of 198 (5.5%) men suffered urinary retention requiring 
catheterization. There was no correlation in healthcare contact 
with age, prostate volume, pain on biopsy, or aspirin use in either 
group (Table 4). There were no deaths in the follow-up period.
As per Clavien-Dindo classification, Grade  I complications 
(antiemetic, fluids, etc.) occurred in 147 men (73.1%), Grade  II 
(antibiotics, blood transfusions, etc.) in 54 men  (26.9%) and there 
were no Grades III–IV complications (surgery, intensive care input or 
death). This was not different across centers (P = 0.35). Overall, there 
was no difference in overall outcomes between patients having a first 
or second biopsy (data not shown).
DISCUSSION
This study adds to the literature on patient-reported outcomes 
following transperineal prostate biopsy. Merrick et al.24 had previously 
demonstrated a higher urinary retention rate but comparable 
outcome to TRUS in terms of urinary, bowel and erectile function. 
Our study had a limited response rate of only 51.6%, and findings 
are based on patient-reported outcomes alone. Some men rated 
post-biopsy pain (4.7%) and infective (fever in 4.9%) or hemorrhagic 
symptoms (hematuria in 6.2%) as a major/moderate problem. Overall, 
attitude to rebiopsy was favorable. Although there was a significant 
increase in men in whom rebiopsy would be a major problem on repeat 
questioning, approximately 7 out of 8 men still had a positive attitude to 
rebiopsy. Bokhorst et al.25 have previously shown that compliance with 
repeat biopsy dramatically decreases with time on active surveillance 
from 81% compliance at year 1 down to 33% in year 10.
Despite being well tolerated on the whole, there were some 
significant side effects. Of those men who suffered one or more 
complication, the majority classified as Clavien Grade  1  (73.1%). 
A  high proportion of men suffered from hemoejaculate  (63.8%), 
which was a moderate/serious problem for 17.4%. Despite the high 
rate of Grade 1 or greater complications, few men contacted healthcare 
providers (7.6%). Interestingly, the rate of urinary retention after TP 
saturation biopsy was only 5.5%. There were no hospital admissions 
and no septic episodes recorded. Similarly, there were no fatalities in 
our study. This is not surprising given the demographics of the men. 
We did not dissect the rates of adverse events between those with a 
cancer diagnosis and those without, but studies have shown this not 
to be the case.4
Table 1: Summary statistics for baseline demographic measures
Characteristics
Number of patients 201
Mean (s.d.) number of cores 27.25 (5.51)
Primary biopsy (%) 56 (27.8)
Secondary biopsy (%) 145 (72.2)
Mean (s.d.) age (year) 64.37 (7.54)
Median (interquartile range) PSA (ng ml−1) 8.3 (5.5–13.8)
Mean (s.d.) HADS (anxiety) 5.43 (3.90)
Mean (s.d.) HADS (depression) 3.73 (2.79)
Median (interquartile range) prostate volume (ml) 49 (32–66)
Mean (s.d.) IIEF (after procedure) 13.24 (9.25)
Mean (s.d.) IPSS (after procedure) 9.37 (6.91)
HADS: hospital anxiety and depression scale; IIEF: International Index of Erectile Function 
(short form‑5); IPSS: International Prostate Symptom Score; s.d.: standard deviation
Table 2: Overall symptoms and significance
a. All reporting symptoms
Symptom present Reporting/respondents Percentage
Pain 94/200 47
Fever 13/201 6.5
Shivers 17/201 8.5
Hematuria 150/200 75
Hematochezia 20/201 10.1
Hemoejaculate 127/201 63.8
Nausea 5/201 2.5
Unwell 27/201 13.4
b. Moderate or severe problem
Pain 9/190 4.7
Fever 9/184 4.9
Shivers 3/185 1.6
Hematuria 12/193 6.2
Hematochezia 2/178 1.1
Hemoejaculate 31/178 17.4
Nausea 1/183 0.5
Unwell 11/181 6.1
Table 3: Urinary and sexual function scores (IPSS, QoL, and IIEF 
scores immediately after biopsy and at follow‑up questioning)
Immediately 
postprocedure
Score (±s.d.) At follow‑up 
questioning
Score (±s.d.) P
TP IPSS 10.2 (±7.16) IPSS 9.37 (±6.91) 0.1934
QoL 1.90 (±1.38) QOL 1.82 (±1.45) 0.5108
IIEF 16.13 (±8.31) IIEF 13.24 (±9.25) <0.001
TP: transperineal; QoL: quality of life; IIEF: International Index of Erectile Function (short 
form‑5); IPSS: International Prostate Symptom Score; s.d.: standard deviation
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Published literature strongly supports our findings. Vyas et al.11 
showed that TP biopsies had a good cancer detection rate (54%) with 
urinary retention in 11 out of 634 men (1.7%) and no cases of urosepsis. 
Negligible rate of urosepsis after TP biopsy has also been reported 
recently with rising rates of post-TRUS sepsis and increased incidence 
of multiresistant bacteria found in rectal flora.26
The results for side effects of our TP biopsy cohort are similar to 
the original ProBE study in patients undergoing TRUS biopsy with 
reference to specific symptoms.4 This is surprising given the men 
having TRUS biopsy in the ProBE study had on average 2 weeks longer 
to recover from the procedure, and we may assume that men after TP 
biopsy possibly have better QoL parameters. Similar to the original 
study, we found that very few men suffered no symptoms (2.1% Grade 0 
in ProBE),4 and in those who did, the vast majority were Grade 1 (64.6% 
in ProBE).4 Again we found that hemoejaculate was a moderate/serious 
problem in a larger than expected proportion of men, but less than the 
20%–26% reported originally.4 After TP biopsy under anesthesia, the 
attitude to rebiopsy was less negative than in ProBE; we found this to 
be up to 12% compared to the nearly 20% in the original publication.4 
Some of these differences may be due to the later timepoint in the 
original study; while we collected data immediately after biopsy and at 
between 7 and 14 days, the ProBE study collected data at 7 and 35 days 
after biopsy.4 Another reason for the change in attitudes or perceived 
problem with hemoejaculate may be that the men are better counseled 
on side effects and rationale for biopsy/rebiopsy in this current cohort 
who are often having a second biopsy (72.2% in our study).
There are several limitations to this work. Firstly, the response rate 
was only 51.6% and follow-up relatively short. There are several reasons 
for this; the main reason for noncompletion of the study was either 
forgetting to fill in questionnaires, not filling in follow-up questionnaire 
or returning documents unfilled. However, the nonresponse rate 
did not seem to bias the data with regards to death rate or hospital 
admissions. A  further criticism is the lack of true “baseline” data 
reflecting the period before biopsy – this represents a shortcoming of 
the study. Therefore while we can draw conclusions about outcomes 
for urinary and sexual matters between the two questionnaires, we 
cannot truly ascertain the true changes from baseline.
Recall bias is a potential problem, but this was limited by the 
relatively short follow-up interval  (between 7 and 14  days). The 
presence of nonspecific symptoms, such as fevers/shivers, may not 
necessarily relate to the biopsy but may influence, for example, attitude 
to repeat biopsy. There was a mixed population of men having first or 
secondary biopsy, which reflects current clinical practice.
Several studies have investigated the effect of TP or TRUS biopsies 
on erectile function and the relationship of prostate biopsies and 
associated anxiety, with the conclusion that prostate biopsies cause 
anxiety and temporary erectile dysfunction,27 which may be worse 
after multiple biopsy episodes.16,28,29 Finally, we did not account for 
co-morbidity, but given this is a relatively young patient cohort, suitable 
for treatment with curative intent, we would expect these not to be a 
significant confounder.
Despite these limitations, we are adding to the literature on 
patient-reported outcomes after TP biopsy using attitude to biopsy as 
a surrogate marker for tolerability and reporting healthcare contact in 
men undergoing TP biopsies under general anesthetic. Local anesthetic 
strategies for TP biopsy are emerging30 and it will be interesting to 
see how anesthesia, lower core numbers, and targeted biopsies only 
may change practice. Prospective studies will be useful to determine 
patient-reported outcome measures after local anesthetic TP biopsy, 
particularly in the era of MRI targeting.
CONCLUSION
The current practice of performing TP biopsy under general anesthetic 
is well tolerated with a good side effect profile and attitude of men 
to repeat biopsy as a marker of tolerability. We can now quantify 
complications and inform patients better of what to expect before 
they embark on the process of general anesthetic transperineal 
prostate biopsy. However, with the possibility of performing local/
regional anesthesia for TP, patient tolerability in this setting is yet to 
be determined. The current study and modified questionnaire could 
act as a benchmark for future work in evaluating patient-reported 
outcomes after local anesthetic TP biopsy.
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